Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totaling 145,900 shares, agrowthof120.7% from the July 31st total of 66,100 shares. Currently,8.7% of the company’s shares are short sold. Based on an average daily volume of 2,270,000 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 2,270,000 shares, the short-interest ratio is presently 0.1 days. Currently,8.7% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded Ainos from a “hold” rating to a “sell” rating in a report on Saturday, August 16th.

Ainos Stock Performance

AIMD stock opened at $3.63 on Friday. Ainos has a 1-year low of $2.00 and a 1-year high of $5.00. The firm has a market cap of $16.92 million, a PE ratio of -0.73 and a beta of 2.25. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 0.96. The business’s 50-day moving average price is $3.14 and its two-hundred day moving average price is $2.86.

Ainos (NASDAQ:AIMD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.99) earnings per share for the quarter.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.